TRDA

$12.59

Post-MarketAs of Mar 17, 8:00 PM UTC

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$12.59
Potential Upside
5%
Whystock Fair Value$13.22
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$482.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-39.13%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
12.20

Recent News

Zacks
Feb 26, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +290.39% and +11.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 24, 2026

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of +11.26% and +2.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 19, 2026

Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 18, 2026

EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?

EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 15, 2026

Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit

Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dys

BEARISH
Negative press. News cycle fixated on risk factors or misses.